Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
140.2 USD | +3.13% | -3.23% | +11.27% |
Sales 2024 * | 425M 455M | Sales 2025 * | 742M 796M | Capitalization | 7.27B 7.8B |
---|---|---|---|---|---|
Net income 2024 * | -236M -253M | Net income 2025 * | 10M 10.72M | EV / Sales 2024 * | 18 x |
Net Debt 2024 * | 390M 418M | Net Debt 2025 * | 323M 346M | EV / Sales 2025 * | 10.2 x |
P/E ratio 2024 * |
-29.7
x | P/E ratio 2025 * |
3,042
x | Employees | 879 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 10.4% |
Latest transcript on Ascendis Pharma A/S
1 day | +3.13% | ||
1 week | -3.23% | ||
Current month | -7.29% | ||
1 month | -7.78% | ||
3 months | +8.48% | ||
6 months | +60.35% | ||
Current year | +11.27% |
Managers | Title | Age | Since |
---|---|---|---|
Jan Mikkelsen
FOU | Founder | 65 | 06-08-31 |
Scott Smith
DFI | Director of Finance/CFO | 50 | 16-08-07 |
Stina Singel
CTO | Chief Tech/Sci/R&D Officer | 50 | 20-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jan Mikkelsen
FOU | Founder | 65 | 06-08-31 |
Albert Cha
CHM | Chairman | 51 | 14-10-31 |
General Counsel | 53 | 07-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.96% | 11 M€ | -6.03% | - | |
0.48% | 0 M€ | 0.00% | - | |
0.45% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 135.9 | -0.75% | 226,133 |
24-04-25 | 136.9 | -4.37% | 376,771 |
24-04-24 | 143.2 | -1.14% | 244,224 |
24-04-23 | 144.8 | +1.92% | 220,120 |
Delayed Quote Nasdaq, April 29, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.27% | 7.76B | |
-2.63% | 103B | |
+1.62% | 95.28B | |
+1.46% | 22.15B | |
-16.67% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.21% | 16.05B | |
+5.41% | 13.68B | |
+33.57% | 12.17B |
- Stock Market
- Equities
- ASND Stock